ECSP12011835A - Moléculas de unión biespecíficas para la terapia anti-angiogénesis. - Google Patents

Moléculas de unión biespecíficas para la terapia anti-angiogénesis.

Info

Publication number
ECSP12011835A
ECSP12011835A ECSP12011835A ECSP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A EC SP12011835 A ECSP12011835 A EC SP12011835A
Authority
EC
Ecuador
Prior art keywords
bispecific
angiogenesis therapy
molecules
dii4
vegf
Prior art date
Application number
Other languages
English (en)
Inventor
Eric Borges
Andreas Gschwind
Joachim Boucneau
Travernier Evelyn De
Joost Kolkman
Pascal Merchiers
Hoorick Diane Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP12011835A publication Critical patent/ECSP12011835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Moléculas de unión biespecíficas, en particular dominios variables sencillos de inmunoglobulina tales como VHH y anticuerpos de dominio, que comprenden un componente de unión a VEGF y un componente de unión a DII4 en una molécula. Composiciones farmacéuticas que contienen los mismos y su uso en el tratamiento de enfermedades que están asociadas con efectos mediados por VEGF y DII4 sobre la angiogénesis. Ácidos nucleicos que codifican las moléculas de unión biespecíficas, células hospedadoras y métodos para prepararlas.
ECSP12011835 2009-10-02 2012-04-26 Moléculas de unión biespecíficas para la terapia anti-angiogénesis. ECSP12011835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03

Publications (1)

Publication Number Publication Date
ECSP12011835A true ECSP12011835A (es) 2012-06-29

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011835 ECSP12011835A (es) 2009-10-02 2012-04-26 Moléculas de unión biespecíficas para la terapia anti-angiogénesis.

Country Status (23)

Country Link
US (2) US20110172398A1 (es)
EP (1) EP2483314A1 (es)
JP (2) JP5833009B2 (es)
KR (1) KR20120101375A (es)
CN (2) CN102639566B (es)
AP (1) AP2012006188A0 (es)
AR (1) AR078515A1 (es)
AU (1) AU2010302589A1 (es)
BR (1) BR112012007239A2 (es)
CA (1) CA2775422A1 (es)
CL (1) CL2012000826A1 (es)
EA (1) EA201200548A1 (es)
EC (1) ECSP12011835A (es)
IL (1) IL218542A0 (es)
IN (1) IN2012DN02752A (es)
MA (1) MA33607B1 (es)
MX (1) MX2012003897A (es)
NZ (2) NZ598956A (es)
PE (1) PE20121024A1 (es)
TN (1) TN2012000145A1 (es)
TW (1) TW201124533A (es)
UY (1) UY32920A (es)
WO (1) WO2011039370A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066694T1 (sl) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
WO2012010551A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068098A1 (en) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
HUE042192T2 (hu) * 2011-09-23 2019-06-28 Oncomed Pharm Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
CN104661679A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
JP6371294B2 (ja) * 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
SG11201503324WA (en) * 2012-11-01 2015-05-28 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations
AU2013337775B2 (en) * 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
EP3020731B1 (en) * 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
US11185583B2 (en) * 2014-02-11 2021-11-30 Albany Medical College Multi-functional mucosal vaccine platform
EP3125937A4 (en) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
JP6967003B2 (ja) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド がんの処置のための方法および組成物
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
BR112018011270A2 (pt) * 2015-12-04 2018-11-21 Univ California anticorpo isolado, composição farmacêutica, e, métodos para tratamento ou redução da taxa de recorrência de um câncer em um paciente e para detecção de células tronco do câncer.
WO2017131230A1 (ja) * 2016-01-29 2017-08-03 国立大学法人京都大学 血小板産生促進剤及びそれを用いた血小板の製造方法
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
TW202120536A (zh) * 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
CN112535738B (zh) * 2020-12-04 2022-09-09 中国科学技术大学 奥沙利铂偶联物及其制备方法和应用
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
CN116063469B (zh) * 2022-08-29 2023-09-22 中山大学 一种寨卡病毒中和性纳米抗体及其制备方法与应用
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
CN117860786A (zh) * 2024-03-12 2024-04-12 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
CN101412759A (zh) * 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
PL3415535T3 (pl) * 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
NZ572177A (en) * 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
KR20090016762A (ko) 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
ZA200809100B (en) * 2006-06-06 2009-12-30 Genentech Inc Anti-DLL4 antibodies and methods using same
ME00591A (en) * 2006-08-07 2011-12-20 Use of dii4 antagonists in ishemic injury or vascular insufficiency
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2121757A2 (en) * 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009124931A2 (en) * 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2012525149A (ja) * 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy

Also Published As

Publication number Publication date
TW201124533A (en) 2011-07-16
AU2010302589A1 (en) 2012-04-19
UY32920A (es) 2011-04-29
KR20120101375A (ko) 2012-09-13
NZ598956A (en) 2014-07-25
WO2011039370A1 (en) 2011-04-07
CL2012000826A1 (es) 2012-10-19
EA201200548A1 (ru) 2012-12-28
BR112012007239A2 (pt) 2019-09-24
CN102639566A (zh) 2012-08-15
IL218542A0 (en) 2012-05-31
CA2775422A1 (en) 2011-04-07
TN2012000145A1 (en) 2013-09-19
IN2012DN02752A (es) 2015-09-18
EP2483314A1 (en) 2012-08-08
PE20121024A1 (es) 2012-08-10
CN105037542A (zh) 2015-11-11
NZ626302A (en) 2015-09-25
AR078515A1 (es) 2011-11-16
CN102639566B (zh) 2015-07-22
JP2016026207A (ja) 2016-02-12
AP2012006188A0 (en) 2012-04-30
MX2012003897A (es) 2012-05-08
MA33607B1 (fr) 2012-09-01
US20110172398A1 (en) 2011-07-14
US20140120095A1 (en) 2014-05-01
JP5833009B2 (ja) 2015-12-16
JP2013506411A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
UY33588A (es) Moleculas de union a vegf
AR078516A1 (es) Moleculas de union a dll-4 (ligando 4 de tipo delta)
UY33997A (es) Moléculas de unión biespecíficas que se unen a dii4 y ang2
BR112014023415A2 (pt) moléculas que se ligam a ang2
CL2008001674A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento.
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201492101A1 (ru) Антитела против fcrn
EA201400579A1 (ru) Антитела к il-36r
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
BR112014024275A2 (pt) "aptâmeros para pdgf e vegf, construtos de aptâmeros e seus usos"
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico